[Problem] There is a demand for a therapeutic method for enhancing the efficacy of a taxane-family anti-tumor agent against various tumors. [Means for Solution] The inventors conducted an investigation on the method for enhancing the anti-tumor effect of taxane-family anti-tumor agents, and as a result, the inventors confirmed that a composition for cancer treatment comprising N 2 -[(2E)-3-(4-chlorophenyl)-2-propenoyl]-N-[2-oxo-2-(4-{[6-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)ethyl]-3-pyridin-2-yl-L-alaninamide (FK330) or a salt thereof as an active ingredient, enhances the anti-tumor effect of taxane-family anti-tumor agents, thus completing the invention. That is, the invention relates to a composition for cancer treatment comprising FK330 or a salt thereof as an active ingredient, which is for combined administration with one or more anti-tumor agents selected from taxane-family anti-tumor agents.탁산계 항종양제의 각종 종양에 대한 약효를 증대시키는 치료 방법이 요구되고 있다.본 발명자는, 탁산계 항종양제의 항종양 작용 증강 방법에 대하여 검토한 결과, N2-[(2E)-3-(4-클로로페닐)-2-프로페노일]-N-[2-옥소-2-(4-{[6-(트리플루오로메틸)피리미딘-4-일]옥시}피페리딘-1-일)에틸]-3-피리딘-2-일-L-알라닌아미드(FK330) 또는 그의 염을 유효 성분으로서 함유하는 암 치료용 조성물이 탁산계 항종양제의 항종양 작용을 증강시키는 것을 확인하여, 본 발명을 완성하였다. 즉, 본원은, 탁산계 항종양제로부터 선택되는 1 이상의 항종양제와의 병용 투여용인, FK330 또는 그의 염을 유효 성분으로서 함유하는 암 치료용 조성물에 관한 것이다.
